Novel Injection Methods (CPB 0777, reviewed 2025-12-02)
Summary
Aetna considers suprachoroidal injection of triamcinolone acetonide injectable suspension (Xipere) medically necessary for macular edema associated with uveitis when the criteria in CPB 1000 are met. Aetna considers suprachoroidal injection of all other pharmacologic agents experimental, investigational or unproven for all indications, and considers sub-retinal injection of recombinant tissue plasminogen activator (rtPA) for the treatment of sub-macular hemorrhage medically necessary. The Mercator Bullfrog micro-infusion device is considered experimental, investigational or unproven for direct adventitial delivery of diagnostic or therapeutic agents via blood vessel walls.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.